Lifitegrast

Lifitegrast Brand Name– XIIDRA

What is Lifitegrast

Lifitegrast ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated to treat signs and symptoms associated with dry eye disease (DED).

During 4 clinical trials comparing lifitegrast to a placebo vehicle, drug recipients noted an improvement in the eye dryness score (EDS) by treatment day 42. In 2 of the 4 studies, the EDS was significantly improved by treatment day 14.

The most common adverse events associated with drug administration include instillation site irritation, dysgeusia, and reduced visual acuity.

Lifitegrast was approved by the FDA for use in patients 17 years and older in July 2016

Indications

  • xerophthalmia

For the treatment of xerophthalmia associated with dry eye disease (keratoconjunctivitis sicca)

Side Effects

  1. anaphylactoid reactions
  2. angioedema
  3. blurred vision
  4. bronchospasm
  5. conjunctival hyperemia
  6. conjunctivitis
  7. dysgeusia
  8. dyspnea
  9. headache
  10. lacrimation
  11. ocular discharge
  12. ocular inflammation
  13. ocular irritation
  14. ocular pruritus
  15. rash
  16. sinusitis
  17. urticaria
  18. visual impairment

Monitoring Parameters

  • ophthalmologic exam

Contraindications

  • breast-feeding
  • contact lenses
  • pregnancy

Lifitegrast should not be administered while wearing contact lenses. Contact lenses should be removed prior to administration of the drug. Lenses may be reinserted 15 minutes following administration of the drug

Interactions

There are no drug interactions associated with Lifitegrast products.

You cannot copy content of this page